Dual treatment of pancreatic adenocarcinoma cells with anti-CD24 mAb and cetuximab enhanced phagocytosis relative to either treatment alone, demonstrating a potential synergy between anti-CD24 mAb and anti-solid-tumor mAbs. This evidence concerns the gene CD24 and pancreatic adenocarcinoma.